Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.79

-1.005 (-14.80%)

15:14
11/29/16
11/29
15:14
11/29/16
15:14

Guggenheim says buy TherapeuticsMD selloff on 'rehash' short thesis

With TherapeuticsMD (TXMD) plunging double-digits following a presentation at the Robin Hood investment conference where the stock was pitched as a short idea, research firm Guggenheim stepped in to defend the stock, calling today's short thesis a "rehash" that fails to recognize nuanced strength of the company's upcoming feminine health products. GUGGENHEIM SAYS CONCERNS MISPLACED, OLD: Guggenheim's Louise Chen defended TherapeuticsMD in an intra-day flash note, calling today's weakness a "compelling buying opportunity." The analyst says the short thesis reportedly presented at the Robin Hood conference by Lakewood's Anthony Bozza, which appears to be driving the selloff, "sounds like a rehash" of a prior thesis published on trading blog Seekingalpha.com in 2012 and 2014. Responding to the "sensational claims" about the company's structure and management, Chen reiterates there is "nothing inherently wrong" with reverse mergers or TherapeuticsMD's executive team, and all would-be issues have been disclosed in regulatory filings. Addressing the bear thesis against the company's drugs, the analyst says any comparisons between its vaginal pain treatment Yuvvexy and Shionogi's Osphena are incorrect, as the Japan-developed competitor needs to be taken a full 12 weeks before producing any results and physicians dislike its systemic nature. Additionally, Chen's research suggests Osphena has secured insurer coverage despite its drawbacks, and she has no reason to believe Yuvvexy, which should gain traction with physicians as an "enhanced next generation product," wouldn't receive coverage. Turning to criticism of TherapeuticsMD's broader menopause drug TX-001HR, which combines estradiol and progesterone to relieve symptoms such as hot flashes, the analyst says FDA approval of the first-in-kind drug would make current combination products prepared under loose regulations by compounding pharmacies "fall foul of DQSA regulations and TX-001HR should take market share." Net-net, Chen says today's bargain could be an "early holiday gift for investors" ahead of what she believes will be positive Q4 data on TX-001HR and potential approval of Yuvvexy in May, both of which she believes "have blockbuster potential that are underappreciated by the Street." PRICE ACTION: After falling sharply shortly after market open, shares of TherapeuticsMD remain down about 16% at $5.73 in afternoon trading.

TXMD TherapeuticsMD
$5.79

-1.005 (-14.80%)

11/07/16
GUGG
11/07/16
INITIATION
Target $33
GUGG
Buy
TherapeuticsMD coverage assumed with a Buy at Guggenheim
Guggenheim analyst Louise Chen assumed coverage on TherapeuticsMD with a Buy and a $33 price target.
11/21/16
OPCO
11/21/16
INITIATION
Target $12
OPCO
Outperform
TherapeuticsMD initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started TherapeuticsMD with an Outperform rating and $12 price target.
11/22/16
JEFF
11/22/16
INITIATION
Target $18
JEFF
Buy
TherapeuticsMD assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of TherapeuticsMD with a Buy rating and $18 price target. The analyst expects positive TX-001HR data in the coming weeks and believes the risk/reward is favorable going into the hormone replacement therapy data.
11/29/16
GUGG
11/29/16
NO CHANGE
GUGG
TherapeuticsMD selloff a buying opportunity, says Guggenheim
Guggenheim analyst Louise Chen believes weakness in TherapeuticsMD is a compelling buying opportunity. Chen said the weakness appears to be driven by a short presentation which sounds like a "rehash" of a prior short thesis published on the blog site "SeekingAlpha.com" with little new information. The analyst expects positive data for TX-001HR in 4Q16, and potential approval for Yuvvexy on its PDUFA date of 5/7/17, both of which she believes have blockbuster potential. Chen has a Buy rating on TherapeuticsMD shares.

TODAY'S FREE FLY STORIES

KFRC

Kforce

$25.50

0.3 (1.19%)

05:15
02/24/17
02/24
05:15
02/24/17
05:15
Downgrade
Kforce rating change  »

Kforce downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$120.70

1.27 (1.06%)

05:14
02/24/17
02/24
05:14
02/24/17
05:14
Upgrade
Intuit rating change  »

Intuit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$24.66

-0.12 (-0.48%)

05:13
02/24/17
02/24
05:13
02/24/17
05:13
Downgrade
HP Enterprise rating change  »

HP Enterprise downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$38.58

-2.68 (-6.50%)

05:13
02/24/17
02/24
05:13
02/24/17
05:13
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGC

Hercules Capital

$14.94

-0.49 (-3.18%)

05:12
02/24/17
02/24
05:12
02/24/17
05:12
Downgrade
Hercules Capital rating change  »

Hercules Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVR

Invesco Mortgage

$15.57

0.08 (0.52%)

05:12
02/24/17
02/24
05:12
02/24/17
05:12
Downgrade
Invesco Mortgage rating change  »

Invesco Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

REG

Regency Centers

$70.95

0.94 (1.34%)

, EQY

Equity One

$31.91

0.39 (1.24%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Equity One to host special shareholder meeting »

Special Shareholder…

REG

Regency Centers

$70.95

0.94 (1.34%)

EQY

Equity One

$31.91

0.39 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

MMM

3M

$187.19

1.15 (0.62%)

, BIOL

BIOLASE

$1.50

-0.02 (-1.32%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Chicago Dental Society to hold a meeting »

Chicago Dental Midwinter…

MMM

3M

$187.19

1.15 (0.62%)

BIOL

BIOLASE

$1.50

-0.02 (-1.32%)

COF

Capital One

$93.41

0.52 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$42.51

-1.83 (-4.13%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Rio Tinto management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

EQY

Equity One

$31.91

0.39 (1.24%)

, REG

Regency Centers

$70.95

0.94 (1.34%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Regency Centers to host special shareholder meeting »

Special Shareholder…

EQY

Equity One

$31.91

0.39 (1.24%)

REG

Regency Centers

$70.95

0.94 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

CASM

CAS Medical

$1.48

-0.01 (-0.67%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CAS Medical management to meet with Craig Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

PBNC

Paragon Commercial

$50.50

-0.35 (-0.69%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Paragon Commercial management to meet with Sandler O'Neill »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SC

Santander Consumer

$14.33

-0.12 (-0.83%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Santander Consumer management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

ELNK

EarthLink

$5.85

0.04 (0.69%)

, WIN

Windstream

$7.29

0.07 (0.97%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.85

0.04 (0.69%)

WIN

Windstream

$7.29

0.07 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

GIS

General Mills

$60.78

0.19 (0.31%)

, TSN

Tyson Foods

$62.82

-0.4 (-0.63%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
The Consumer Analyst Group of New York to hold a conference »

2017 CAGNY Conference is…

GIS

General Mills

$60.78

0.19 (0.31%)

TSN

Tyson Foods

$62.82

-0.4 (-0.63%)

TWNK

Hostess Brands

$15.78

0.31 (2.00%)

MJN

Mead Johnson

$87.61

0.11 (0.13%)

K

Kellogg

$74.80

0.31 (0.42%)

MDLZ

Mondelez

$44.89

0.24 (0.54%)

INGR

Ingredion

$122.28

1.66 (1.38%)

LNCE

Snyder's-Lance

$39.60

0.17 (0.43%)

SYY

Sysco

$52.89

0.14 (0.27%)

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

SJM

J.M. Smucker

$140.83

0.1 (0.07%)

MO

Altria Group

$74.46

0.86 (1.17%)

CPB

Campbell Soup

$59.06

-0.11 (-0.19%)

PEP

PepsiCo

$109.54

0.13 (0.12%)

CLX

Clorox

$135.83

-0.09 (-0.07%)

BG

Bunge

$80.05

0.61 (0.77%)

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

DANOY

Danone

$13.34

0.13 (0.98%)

SPB

Spectrum Brands

$137.26

0.97 (0.71%)

KO

Coca-Cola

$41.66

0.06 (0.14%)

IFF

International Flavors

$125.14

2.51 (2.05%)

STZ

Constellation Brands

$153.60

-6.6 (-4.12%)

NSRGY

Nestle

$74.20

0.4 (0.54%)

CHD

Church & Dwight

$49.62

-0.07 (-0.14%)

UN

Unilever; also tag UL

$46.58

-0.17 (-0.36%)

CL

Colgate-Palmolive

$74.44

0.95 (1.29%)

NWL

Newell Brands

$46.80

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 19

    Mar

  • 27

    Mar

  • 09

    May

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CLSA to hold a forum »

Japan Forum is being held…

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
CLSA financial tech analyst holds an analyst/industry conference call »

Financial Technology…

AGN

Allergan

$246.33

0.71 (0.29%)

, EDGE

Edge Therapeutics

$10.00

-0.27 (-2.63%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
American Heart Association to hold a conference »

International Stroke…

AGN

Allergan

$246.33

0.71 (0.29%)

EDGE

Edge Therapeutics

$10.00

-0.27 (-2.63%)

AMGN

Amgen

$174.01

1.4 (0.81%)

ATRC

AtriCure

$17.35

0.13 (0.75%)

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

DNA

Bought by RHHBY

MDCO

The Medicines Co.

$51.84

-0.38 (-0.73%)

MDT

Medtronic

$80.74

1.12 (1.41%)

MRK

Merck

$65.85

0.56 (0.86%)

PH

Parker-Hannifin

$153.70

-2.16 (-1.39%)

PTLA

Portola Pharmaceuticals

$32.16

0.02 (0.06%)

Q

QuintilesIMS

$78.12

0.77 (1.00%)

SSNLF

Samsung

SAY

Satyam

TWTR

Twitter

$16.03

-0.05 (-0.31%)

WTKWY

Wolters Kluwer

$40.39

0.502 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    May

  • 10

    May

  • 27

    May

  • 14

    Jun

  • 24

    Jun

  • 19

    Jul

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Wells Fargo housing analyst holds an analyst/industry conference call »

Senior Housing Analyst…

NVO

Novo Nordisk

$35.78

0.53 (1.50%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Novo Nordisk management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

KAR

KAR Auction

$44.50

-0.3 (-0.67%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
KAR Auction management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

04:55
02/24/17
02/24
04:55
02/24/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

February Consumer…

04:55
02/24/17
02/24
04:55
02/24/17
04:55
General news
New Home Sales to be reported at 10:00 »

January New Home Sales…

VWDRY

Vestas

$25.08

0.175 (0.70%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Vestas management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

HSIC

Henry Schein

$171.92

-0.72 (-0.42%)

04:55
02/24/17
02/24
04:55
02/24/17
04:55
Conference/Events
Henry Schein management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.